vs
SIERRA BANCORP（BSRR）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
SIERRA BANCORP的季度营收约是REGENXBIO Inc.的1.3倍（$39.3M vs $30.3M），SIERRA BANCORP净利率更高（40.4% vs -221.3%，领先261.7%），REGENXBIO Inc.同比增速更快（43.0% vs 3.8%），SIERRA BANCORP自由现金流更多（$32.2M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 2.6%）
Sierra Bancorp是总部位于美国加利福尼亚州的地区性银行控股公司，运营Bank of the Sierra品牌，提供存款、消费贷款、商业信贷、按揭等零售及商业银行业务，主要服务加州中南部的本地社区、中小企业及个人客户。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BSRR vs RGNX — 直观对比
营收规模更大
BSRR
是对方的1.3倍
$30.3M
营收增速更快
RGNX
高出39.2%
3.8%
净利率更高
BSRR
高出261.7%
-221.3%
自由现金流更多
BSRR
多$85.0M
$-52.8M
两年增速更快
RGNX
近两年复合增速
2.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $39.3M | $30.3M |
| 净利润 | $12.9M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 43.6% | -190.0% |
| 净利率 | 40.4% | -221.3% |
| 营收同比 | 3.8% | 43.0% |
| 净利润同比 | 24.4% | -31.2% |
| 每股收益（稀释后） | $0.96 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BSRRRGNX
| Q4 25 | $39.3M | $30.3M | ||
| Q3 25 | $40.0M | $29.7M | ||
| Q2 25 | $39.2M | $21.4M | ||
| Q1 25 | $36.8M | $89.0M | ||
| Q4 24 | $37.9M | $21.2M | ||
| Q3 24 | $38.6M | $24.2M | ||
| Q2 24 | $37.8M | $22.3M | ||
| Q1 24 | $37.3M | $15.6M |
净利润BSRRRGNX
| Q4 25 | $12.9M | $-67.1M | ||
| Q3 25 | $9.7M | $-61.9M | ||
| Q2 25 | $10.6M | $-70.9M | ||
| Q1 25 | $9.1M | $6.1M | ||
| Q4 24 | $10.4M | $-51.2M | ||
| Q3 24 | $10.6M | $-59.6M | ||
| Q2 24 | $10.3M | $-53.0M | ||
| Q1 24 | $9.3M | $-63.3M |
毛利率BSRRRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率BSRRRGNX
| Q4 25 | 43.6% | -190.0% | ||
| Q3 25 | 31.7% | -176.3% | ||
| Q2 25 | 36.3% | -296.3% | ||
| Q1 25 | 33.4% | 13.6% | ||
| Q4 24 | 33.3% | -242.1% | ||
| Q3 24 | 37.4% | -256.6% | ||
| Q2 24 | 37.6% | -251.3% | ||
| Q1 24 | 33.9% | -408.8% |
净利率BSRRRGNX
| Q4 25 | 40.4% | -221.3% | ||
| Q3 25 | 24.2% | -208.3% | ||
| Q2 25 | 27.1% | -331.8% | ||
| Q1 25 | 24.8% | 6.8% | ||
| Q4 24 | 34.1% | -241.3% | ||
| Q3 24 | 27.5% | -246.3% | ||
| Q2 24 | 27.2% | -237.7% | ||
| Q1 24 | 25.0% | -405.4% |
每股收益（稀释后）BSRRRGNX
| Q4 25 | $0.96 | $-1.30 | ||
| Q3 25 | $0.72 | $-1.20 | ||
| Q2 25 | $0.78 | $-1.38 | ||
| Q1 25 | $0.65 | $0.12 | ||
| Q4 24 | $0.73 | $-0.99 | ||
| Q3 24 | $0.74 | $-1.17 | ||
| Q2 24 | $0.71 | $-1.05 | ||
| Q1 24 | $0.64 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $135.6M | $230.1M |
| 总债务越低越好 | $49.5M | — |
| 股东权益账面价值 | $364.9M | $102.7M |
| 总资产 | $3.8B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.14× | — |
8季度趋势，按日历期对齐
现金及短期投资BSRRRGNX
| Q4 25 | $135.6M | $230.1M | ||
| Q3 25 | $95.5M | $274.2M | ||
| Q2 25 | $130.0M | $323.3M | ||
| Q1 25 | $159.7M | $267.9M | ||
| Q4 24 | $100.7M | $234.7M | ||
| Q3 24 | $132.8M | $255.5M | ||
| Q2 24 | $184.0M | $290.4M | ||
| Q1 24 | $119.2M | $338.7M |
总债务BSRRRGNX
| Q4 25 | $49.5M | — | ||
| Q3 25 | $49.5M | — | ||
| Q2 25 | $49.4M | — | ||
| Q1 25 | $49.4M | — | ||
| Q4 24 | $49.4M | — | ||
| Q3 24 | $49.4M | — | ||
| Q2 24 | $49.3M | — | ||
| Q1 24 | $49.3M | — |
股东权益BSRRRGNX
| Q4 25 | $364.9M | $102.7M | ||
| Q3 25 | $360.1M | $161.5M | ||
| Q2 25 | $355.7M | $213.7M | ||
| Q1 25 | $351.8M | $274.2M | ||
| Q4 24 | $357.3M | $259.7M | ||
| Q3 24 | $358.7M | $301.4M | ||
| Q2 24 | $350.0M | $348.3M | ||
| Q1 24 | $345.1M | $390.7M |
总资产BSRRRGNX
| Q4 25 | $3.8B | $453.0M | ||
| Q3 25 | $3.7B | $525.2M | ||
| Q2 25 | $3.8B | $581.0M | ||
| Q1 25 | $3.6B | $490.9M | ||
| Q4 24 | $3.6B | $466.0M | ||
| Q3 24 | $3.7B | $519.1M | ||
| Q2 24 | $3.7B | $569.4M | ||
| Q1 24 | $3.6B | $629.2M |
负债/权益比BSRRRGNX
| Q4 25 | 0.14× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.14× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $33.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $32.2M | $-52.8M |
| 自由现金流率自由现金流/营收 | 81.9% | -174.0% |
| 资本支出强度资本支出/营收 | 3.9% | 1.7% |
| 现金转化率经营现金流/净利润 | 2.61× | — |
| 过去12个月自由现金流最近4个季度 | $50.8M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BSRRRGNX
| Q4 25 | $33.7M | $-52.3M | ||
| Q3 25 | $14.9M | $-56.0M | ||
| Q2 25 | $-35.9M | $-49.3M | ||
| Q1 25 | $40.6M | $33.6M | ||
| Q4 24 | $57.2M | $-31.6M | ||
| Q3 24 | $27.4M | $-40.5M | ||
| Q2 24 | $620.0K | $-45.5M | ||
| Q1 24 | $7.0M | $-55.5M |
自由现金流BSRRRGNX
| Q4 25 | $32.2M | $-52.8M | ||
| Q3 25 | $14.7M | $-56.5M | ||
| Q2 25 | $-36.3M | $-49.7M | ||
| Q1 25 | $40.2M | $32.6M | ||
| Q4 24 | $56.0M | $-32.7M | ||
| Q3 24 | $27.3M | $-40.9M | ||
| Q2 24 | $202.0K | $-46.0M | ||
| Q1 24 | $6.6M | $-56.0M |
自由现金流率BSRRRGNX
| Q4 25 | 81.9% | -174.0% | ||
| Q3 25 | 36.7% | -189.9% | ||
| Q2 25 | -92.6% | -232.8% | ||
| Q1 25 | 109.5% | 36.6% | ||
| Q4 24 | 147.9% | -154.2% | ||
| Q3 24 | 70.7% | -168.9% | ||
| Q2 24 | 0.5% | -206.2% | ||
| Q1 24 | 17.7% | -358.5% |
资本支出强度BSRRRGNX
| Q4 25 | 3.9% | 1.7% | ||
| Q3 25 | 0.6% | 1.7% | ||
| Q2 25 | 1.2% | 1.8% | ||
| Q1 25 | 1.0% | 1.2% | ||
| Q4 24 | 3.1% | 5.1% | ||
| Q3 24 | 0.3% | 1.3% | ||
| Q2 24 | 1.1% | 2.1% | ||
| Q1 24 | 1.0% | 3.6% |
现金转化率BSRRRGNX
| Q4 25 | 2.61× | — | ||
| Q3 25 | 1.54× | — | ||
| Q2 25 | -3.37× | — | ||
| Q1 25 | 4.46× | 5.53× | ||
| Q4 24 | 5.51× | — | ||
| Q3 24 | 2.58× | — | ||
| Q2 24 | 0.06× | — | ||
| Q1 24 | 0.75× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BSRR
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
